4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI

Suneil Jain; Danielle Croucher; Jack  Murphy; Ross  Murphy; Xiaoxuan  Yang; Dibya Mukherjee; Anna Jurek Loughrey; Erin L.  Stewart; Trevor J. Royce; Timothy N  Showalter; Andre Esteva; Felix  Feng; Emma Allott

doi:10.1016/S0167-8140(25)03080-4

4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI

Suneil Jain
, Danielle Croucher
, Jack Murphy
, Ross Murphy
, Xiaoxuan Yang
, Dibya Mukherjee
, Anna Jurek Loughrey^*
, Erin L. Stewart
, Trevor J. Royce
, Timothy N Showalter
, Andre Esteva
, Felix Feng
, Emma Allott

^*Corresponding author for this work

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	S2090-S2092
Number of pages	3
Journal	Radiotherapy and Oncology
Volume	206
Issue number	Supplement 1
DOIs	https://doi.org/10.1016/S0167-8140(25)03080-4
Publication status	Published - 21 May 2025
Event	ESTRO 2025, 2-6 May 2025, Vienna, Austria - Vienna, Austria Duration: 02 May 2025 → 06 May 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0167-8140(25)03080-4Licence: Unspecified

Cite this

Jain, S., Croucher, D., Murphy, J., Murphy, R., Yang, X., Mukherjee, D., Jurek Loughrey, A., Stewart, E. L., Royce, T. J., Showalter, T. N., Esteva, A., Feng, F., & Allott, E. (2025). 4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI. Radiotherapy and Oncology, 206(Supplement 1), S2090-S2092. https://doi.org/10.1016/S0167-8140(25)03080-4

@article{790f47e8b4d14b56a104ebb843361458,

title = "4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI",

author = "Suneil Jain and Danielle Croucher and Jack Murphy and Ross Murphy and Xiaoxuan Yang and Dibya Mukherjee and \{Jurek Loughrey\}, Anna and Stewart, \{Erin L.\} and Royce, \{Trevor J.\} and Showalter, \{Timothy N\} and Andre Esteva and Felix Feng and Emma Allott",

year = "2025",

month = may,

day = "21",

doi = "10.1016/S0167-8140(25)03080-4",

language = "English",

volume = "206",

pages = "S2090--S2092",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

publisher = "Elsevier Ireland Ltd",

number = "Supplement 1",

note = "ESTRO 2025, 2-6 May 2025, Vienna, Austria ; Conference date: 02-05-2025 Through 06-05-2025",

}

Jain, S, Croucher, D, Murphy, J, Murphy, R, Yang, X, Mukherjee, D, Jurek Loughrey, A, Stewart, EL, Royce, TJ, Showalter, TN, Esteva, A, Feng, F & Allott, E 2025, '4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI', Radiotherapy and Oncology, vol. 206, no. Supplement 1, pp. S2090-S2092. https://doi.org/10.1016/S0167-8140(25)03080-4

4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI. / Jain, Suneil; Croucher, Danielle; Murphy, Jack et al.
In: Radiotherapy and Oncology, Vol. 206, No. Supplement 1, 21.05.2025, p. S2090-S2092.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - 4012 Characterization of MMAI risk and treatment benefit in a contemporary UK localised prostate cancer cohort diagnosed with pre-biopsy biparametric MRI

AU - Jain, Suneil

AU - Croucher, Danielle

AU - Murphy, Jack

AU - Murphy, Ross

AU - Yang, Xiaoxuan

AU - Mukherjee, Dibya

AU - Jurek Loughrey, Anna

AU - Stewart, Erin L.

AU - Royce, Trevor J.

AU - Showalter, Timothy N

AU - Esteva, Andre

AU - Feng, Felix

AU - Allott, Emma

PY - 2025/5/21

Y1 - 2025/5/21

U2 - 10.1016/S0167-8140(25)03080-4

DO - 10.1016/S0167-8140(25)03080-4

M3 - Meeting abstract

SN - 0167-8140

VL - 206

SP - S2090-S2092

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - Supplement 1

T2 - ESTRO 2025, 2-6 May 2025, Vienna, Austria

Y2 - 2 May 2025 through 6 May 2025

ER -